Given that the FDA said data for CD10 Mild/Moderat

Given that the FDA said data for CD10 Mild/Moderate wouldn't warrant an EUA, as the populations weren't in imminent danger and there were already approved treatments, what would make you think the CEO wouldn't (likewise) consult with the FDA for CD12, given that the only approved treatment is Dex and the Severe/Critical are facing death, the definition of imminent danger?

Reads like cognitive dissonance.